MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
VistaGen Therapeutics Cash and Cash Equivalents 2011-2026 | VTGN
Annual Cash and Cash Equivalents VistaGen Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.1 M | 119 M | 16.6 M | 68.1 M | 103 M | 1.36 M | 13.1 M | 10.4 M | 2.92 M | 428 K | 70 K | - | 638 K | 81 K | 139 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 70 K | 28.8 M |
Quarterly Cash and Cash Equivalents VistaGen Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.4 M | 62.8 M | 49 M | 74.7 M | 84.2 M | 103 M | 127 M | 37.6 M | 9.62 M | 16.6 M | 25 M | 35.3 M | 52 M | 68.1 M | 83.7 M | 93.6 M | 97.8 M | 103 M | 104 M | 15.4 M | 1.55 M | 1.55 M | 1.06 M | 1.06 M | 4.07 M | 8.3 M | 6.29 M | 6.29 M | 7.83 M | 10.4 M | 13 M | 1.76 M | 1.63 M | 2.92 M | 4.37 M | 6.26 M | 8.5 M | 428 K | 1.16 M | 694 K | 121 K | 70 K | 13.2 K | - | 401 K | - | 20.7 K | 6.5 K | 89.8 K | 638 K | 24.2 K | 13.4 K | 31.7 K | 81 K | 166 K | 94.5 K | 94.5 K | 139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 127 M | 6.5 K | 24.7 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 34.55 | 2.04 % | $ 2.29 B |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 4.47 | 12.59 % | $ 10.8 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
2.6 M | $ 5.8 | 13.28 % | $ 391 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 6.68 | -12.79 % | $ 66 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 309.66 | -3.27 % | $ 40.6 B | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 22.88 | 4.91 % | $ 1.07 B | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 102.92 | 0.78 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
28.4 M | $ 1.15 | 7.48 % | $ 14 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
185 M | $ 1.41 | 4.07 % | $ 363 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.32 | 1.41 % | $ 462 M | USA |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 24.53 | 1.41 % | $ 3.12 B | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 4.96 | 6.1 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
83 M | $ 3.44 | -2.27 % | $ 346 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.6 | -0.62 % | $ 426 M | Britain |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
3.25 M | $ 0.86 | 0.39 % | $ 5.79 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
190 M | - | - | $ 1.41 B | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |